NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free IMNN Stock Alerts $1.44 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.38▼$1.4850-Day Range$0.52▼$1.9352-Week Range$0.48▼$2.00Volume49,331 shsAverage Volume201,647 shsMarket Capitalization$13.54 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Imunon alerts: Email Address Imunon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside802.8% Upside$13.00 Price TargetShort InterestHealthy4.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.27) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.05 out of 5 starsMedical Sector794th out of 914 stocksPharmaceutical Preparations Industry366th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingImunon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImunon has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.96% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 4.53%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Imunon this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for IMNN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.84% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.47% of the stock of Imunon is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($2.27) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Imunon Stock (NASDAQ:IMNN)Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.Read More IMNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNN Stock News HeadlinesApril 25, 2024 | americanbankingnews.comImunon (NASDAQ:IMNN) Trading Down 2.3%April 18, 2024 | finance.yahoo.comIMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101April 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.April 18, 2024 | globenewswire.comIMUNON's IND Application Cleared to Begin Human Testing of IMNN-101April 11, 2024 | finanznachrichten.deImunon, Inc.: IMUNON Reports Compliance with Nasdaq Listing RequirementsApril 11, 2024 | globenewswire.comIMUNON Reports Compliance with Nasdaq Listing RequirementsMarch 30, 2024 | seekingalpha.comImunon, Inc. (IMNN) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | globenewswire.comIMUNON Reports 2023 Financial Results and Provides Business UpdateApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 25, 2024 | globenewswire.comIMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating LossesMarch 21, 2024 | globenewswire.comIMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024March 15, 2024 | finanznachrichten.deImunon, Inc.: IMUNON Announces Leadership ChangeMarch 14, 2024 | uk.investing.comIMUNON CEO steps down, Executive Chairman takes helmMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Imunon (IMNN) and CalciMedica (CALC)March 13, 2024 | globenewswire.comIMUNON Files IND Application to Begin Human Testing of IMNN-101March 12, 2024 | globenewswire.comIMUNON Announces Leadership ChangeMarch 2, 2024 | uk.investing.comIMUNON reports promising vaccine study resultsFebruary 29, 2024 | globenewswire.comIndependent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5February 28, 2024 | benzinga.comWhy Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionFebruary 28, 2024 | msn.comIMUNON continues subject enrolment in Phase I/II ovarian cancer trialFebruary 27, 2024 | finance.yahoo.comMemorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerFebruary 27, 2024 | globenewswire.comMemorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerFebruary 22, 2024 | globenewswire.comIMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal VaccineFebruary 16, 2024 | wsj.comBicycle Therapeutics Ltd. ADRDecember 11, 2023 | finance.yahoo.comIMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 20, 2023 | finance.yahoo.comImunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call TranscriptNovember 17, 2023 | msn.comIMNN: Promising Interim PFS and OS Data for IMNN-001 in OVATION 2 Trial… - MSNSee More Headlines Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/27/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMNN CUSIPN/A CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees31Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$13.00 Low Stock Price Target$13.00 Potential Upside/Downside+802.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,510,000.00 Net MarginsN/A Pretax Margin-23,541.60% Return on Equity-98.04% Return on Assets-66.49% Debt Debt-to-Equity RatioN/A Current Ratio2.47 Quick Ratio2.47 Sales & Book Value Annual Sales$500,000.00 Price / Sales27.07 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book1.01Miscellaneous Outstanding Shares9,400,000Free Float9,039,000Market Cap$13.54 million OptionableNot Optionable Beta2.03 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Michael H. Tardugno (Age 73)Executive Chairman Comp: $1.58MMr. Jeffrey W. Church CPA (Age 67)CFO, Executive VP & Corporate Secretary Comp: $548.92kDr. Khursheed Anwer M.B.A. (Age 64)Ph.D., Executive VP & Chief Scientific Officer Comp: $540.87kMr. Timothy J. Tumminello CPA (Age 66)Chief Accounting Officer & Controller Comp: $108.31kMs. Marianne M. LambertsonVice President of Communications & Investor RelationsDr. Sebastien Hazard M.D. (Age 52)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsPurple BiotechNASDAQ:PPBTRedHill BiopharmaNASDAQ:RDHLMIRA PharmaceuticalsNASDAQ:MIRAAgeX TherapeuticsNYSE:AGETonix PharmaceuticalsNASDAQ:TNXPView All Competitors IMNN Stock Analysis - Frequently Asked Questions Should I buy or sell Imunon stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Imunon in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMNN shares. View IMNN analyst ratings or view top-rated stocks. What is Imunon's stock price target for 2024? 1 Wall Street analysts have issued twelve-month price objectives for Imunon's stock. Their IMNN share price targets range from $13.00 to $13.00. On average, they predict the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 802.8% from the stock's current price. View analysts price targets for IMNN or view top-rated stocks among Wall Street analysts. How have IMNN shares performed in 2024? Imunon's stock was trading at $0.68 at the beginning of the year. Since then, IMNN shares have increased by 111.8% and is now trading at $1.44. View the best growth stocks for 2024 here. When is Imunon's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IMNN earnings forecast. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) issued its earnings results on Thursday, March, 28th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.07. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
